Description
(AWP Alliance News) - Cosmo announced positive Phase 2 results on October 19, 2026, for its rifamycin 1% topical gel in distal ulcerative colitis and ulcerative proctitis. The treatment met the primary endpoint, with significantly more patients achieving clinical remission than with placebo.
The gel was well tolerated, with no unexpected safety findings or treatment-related serious adverse events. Discussions with the FDA and EMA will guide Phase 3 planning.
Topline results have been announced; full results will be presented at upcoming major medical meetings or congresses.
https://docs.publicnow.com/4D837BAF60B8A3B79A98C6F48185FDBE0C1E59A7
Disclaimer: This news brief was created using generative artificial intelligence. Cosmo NV published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.
